INVESTIGATION OF FACTORS AFFECTING ADHERENCE TO METFORMIN THERAPY IN TYPE 2 DIABETES

Aldijana Mahmutović; Lana Lekić; Nermina Zaimović Imamović; Amir Kikanović; Ana Pavlović

doi:10.35120/medisij030243m

Authors

Aldijana Mahmutović Cantonal Administration for Inspection Affairs of Tuzla Canton, Bosnia and Herzegovina
Lana Lekić Faculty of Health Studies, University of Sarajevo,Sarajevo, Bosnia and Herzegovina
Nermina Zaimović Imamović Public Health Institution “Health Center” Lukavac, Bosnia and Herzegovina
Amir Kikanović Public Health Institution “Health Center” Lukavac, Bosnia and Herzegovina
Ana Pavlović Professional physiotherapist

DOI:

https://doi.org/10.35120/medisij030243m

Keywords:

diabetes, adherence, patients, factors, metformin

Abstract

Adherence is the degree to which the patient’s behavior (taking medication, following a diet, and/or changing lifestyle) matches the agreed recommendations of the prescriber. Adherence is influenced by socio-economic factors, factors related to the health system, factors related to the disease, factors related to the patient and factors related to therapy. Many methods have been developed to measure adherence. Methods are divided into direct and indirect. Adherence is usually lower in patients with chronic conditions than in patients with acute conditions. More recent studies show adherence values to oral antidiabetic therapy of 65-85%. Adherence is usually considered optimal when patients take at least 80% of their prescribed medication. The research conducted on the sample made up of middle-aged, non-adherent respondents (35-65), who have been using metformin for a minimum of 6 months in the treatment of type 2 diabetes mellitus showed the influence of different factors on adherence. The factors that showed the greatest influence on the low degree of adherence are: lower education, passive life, low physical activity, smoking, long-term therapy, change of therapy, concomitant therapy, metformin dosing more than 2 times a day, forgetting to take therapy. The average value of blood sugar for all subjects is 10.5 mmol/L, which indicates the ineffectiveness of the prescribed therapy, and which can be directly linked to the determined non-adherence of subjects to metformin therapy.

Downloads

Download data is not yet available.

References

ABC Project. (2012). Ascertaining Barriers for Compliance: policies for safe, effective and cost-effective use of medicines in Europe. Final report of the ABC Project. available at: http://abcproject.eu/img/ABC%20Final.pdf

American Diabetes Association. (2010). Diagnosis and Classiffication od Diabetes Mellitus. Diabetes Care, 33 (Suppl1), S62-9.

Boccuzzi, S. Wogen, J. Fox, J. Sung, J. Shah, A. Kim, J. (2001). Utilization of oral hypoglycemic agents in a drug-insured US population. Diabetes Care, 24(8), 1411-5.

Borgsteede, S.D., Westerman, M.J., Kok, I.L., Meeuse, J.C., de Vries, T.P., Hugtenburg. J.G. (2011). Factors related to high and low levels of drug adherence according to patients with type 2 diabetes. Int J Clin Pharm, 33(5), 779-87.

Caro, J.J., Ishak, K.J., Huybrechts, K.F., Raggio, G., Naujoks, C. (2004). The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int.,15, 1003–8.

Cramer, J.A. (2004). A systematic review of adherence with medications for diabetes. Diabetes Care, 27, 1218–24.

Čulig, J., Leppée, M., Skaron, N., Malovic, M., Bilusic, M. (2012). Patients’ adherence to medication rate and macoeconomic analysis. Pharmaca, 50(Supl.1), 48.

Dezii, C.M., Kawabata, H., Tran, M. (2002). Effects of once daily and twice-daily dosing on adherence with prescribed glipizide oral therapy for type 2 diabetes. South Med J., 95, 68–71.

Donnan, P.T., MacDonald, T.M., Morris, A.D. (2002). Adherence to prescribed oral hypoglycaemic medication in a population of patients with type 2 diabetes: a retrospective cohort study. Diabet Med.,19(4), 279–84.

Doro, P., Benko, R., Kosik, E., Matuz, M., Toth, K., Soos, G. (2005). Utilization of oral antihyperglycemic drugs over a 7-year period (1998-2004) in a Hungarian population and adherence to drug therapy. Eur J Clin Pharmacol., 61(12), 893-7.

García-Pérez, L.E., Alvarez, M., Dilla, T., Gil-Guillén, V., Orozco-Beltrán, D. (2013). Adherence to therapies in patients with type 2 diabetes. Diabetes Ther., 4(2), 175-94.

Haynes, R.B., Taylor, D.W., Sackett, D.L., Gibson, E.S., Bernholz, C.D., Mukherjee, J. (1980). Can simple clinical measurements detect patient noncompliance? Hypertension, 2, 757- 64.

Horne, R., Weinman, J. (1999). Patients’ beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res., 47, 555-67.

Hutchins, V., Zhang, B., Fleurence, R.L., Krishnarajah, G., Graham, J. (2011). A systematic review of adherence, treatment satisfaction and costs, in fixed-dose combination regimens in type 2 diabetes. Curr Med Res Opin., 27, 1157–68.

International Diabetes Federation. (2015). IDF DIABETES ATLAS. 7th ed.

Leiter, L.A., & Nauck, M.A. (2017). Efficacy and Safety of GLP-1 Receptor Agonists Across the Spectrum of Type 2 Diabetes Mellitus. Exp Clin Endocrinol Diabetes, 125(7), 419-35.

Mason, B.J., Matsuyama, J.R., Jue, S.G. (1995). Assessment of sulfonylurea adherence and metabolic control. Diabetes Educ., 21(1), 52-7.

Matsuyama, J.R., Mason, B.J., Jue, S.G. (1993). Pharmacists’ interventions using electronic medicationevent monitoring device’s adherence data versus pill counts. Ann Pharmacother., 27, 851–5.

Miller, W., & Rollnick S. (1999). Motivational interviewing. New York: Guilford Press.

Morsi, M., Maher, A., Aboelmagd, O., Johar, D., Bernstein, L. (2018). A Shared Comparison of Diabetes Mellitus and Neurodegenerative Disorders. J Cell Biochem., 119(2), 1249-56.

Naderi, S.H., Bestwick, J.P., Wald, D.S. (2012). Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Am J Med., 125(9), 882-887.

Osterberg, L., Blaschke, T. (2005) Adherence to medication. N Engl J Med., 353(5), 487-497.

Paes, A. H., Bakker, A., Soe-Agnie, C. J. (1997). Impact of dosage frequency on patient compliance. Diabetes Care., 20(10), 1512-7.

Petersen, M.C., Vatner, D.F., Shulman, G.I. (2017). Regulation of hepatic glucose metabolism in health and disease. Nat Rev Endocrinol., 13(10), 572-87.

Pladevall, M., Williams, L.K., Potts, L.A., Divine, G., Xi, H., Lafata, J.E. (2004). Clinical outcomes and adherence to medications measured by claims data in patients with diabetes. Diabetes Care, 27(12), 2800-5.

Rašković, A. (2015). Farmakologija za studije zdravstvene nege. Novi Sad: Alfagraf.

Sackett, D.L., Snow, J.C. (1979). The magnitude of compliance and noncompliance. In: Haynes, R.B., Sackett, D.L., Taylor, D.W., editors. Compliance in Health Care. Baltimore: Johns Hopkins Univ Pr, 11-22.

Schectman, J.M., Nadkarni, M.M., Voss, J.D. (2002). The association between diabetes metabolic control and drug adherence in an indigent population. Diabetes Care, 25, 1015–21.

Spoelstra, J.A., Stolk, R.P., Heerdink, E.R., Klungel, O.H., Erkens, J.A., Leufkens, H.G., et al. (2003). Refill compliance in type 2 diabetes mellitus: a predictor of switching to insulin therapy? Pharmacoepidemiol Drug Saf., 12, 121–7.

World Health Organization. (2003). Adherence to long-term therapies evidence for action. World Health Organization.